![](https://news.europawire.eu/wp-content/uploads/2013/10/AstraZeneca-144x150.jpg)
LONDON, 2-12-2014 — /EuropaWire/ — AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for IRESSA® (gefitinib) as a targeted monotherapy for the first line treatment of patients with … Read the full press release